Section 271(e)(1) Safe Harbor Applies to Importation Regardless of Intent or Actual Use

April 18, 2024

Reading Time : 3 min

A divided panel of the Federal Circuit affirmed a district court’s grant of summary judgment of noninfringement, holding that importation of two product samples into the U.S. was reasonably related to obtaining FDA approval based on the particular facts of this case. In dissent, Judge Lourie disagreed, suggesting that summary judgment was not appropriate where factual disputes existed as to whether the importation was “solely” for purposes related to FDA approval.

At issue in this case was the importation of two sample heart valve systems. The accused infringer brought the samples into the U.S. in connection with a medical trade show. It was undisputed, however, that the samples were never shown at the trade show. It was also undisputed that the accused infringer never offered for sale or sold the samples. And in advance of the trade show, the accused infringer instructed its employees that they could not make offers for sale in the U.S. But the employees were permitted to make offers for other countries where the systems were already approved for human use. According to the accused infringer, it brought the samples to the U.S. trade show to identify potential clinicians for its premarket approval application who were known to attend the trade show. In support of this assertion, the accused infringer presented evidence that it started work on a premarket approval submission, began planning a “Landmark Trial” to include in future submissions to the FDA, contacted the FDA about the requirements for a premarket submission and retained a medical device consulting company to assist with its premarket submission.

Based on these facts, the district court found the accused infringer’s activities were protected by the Safe Harbor provision, and granted summary judgment of non-infringement. 

On appeal, the patentee argued the district court failed to apply an objective standard to the Safe Harbor and instead improperly relied on the accused infringer’s intent. The Federal Circuit rejected this argument, explaining that “the relevant inquiry is not why” the accused infringer imported the samples “or how” it used the samples, “but whether the act of importation was for a use reasonably related to submitting information to the FDA.” In view of the undisputed evidence that no offers for sale were made, the court held that no reasonably minded juror could have concluded the importation was “solely to support commercial sales, rather than to recruit clinical investigators.” According to the majority, “solely” as used in the Safe Harbor modifies uses and means, for each act of infringement, the safe harbor is available where the acts or uses that constitute infringement bear a reasonable relation to the development and submission of information to the FDA.

On this point, Judge Lourie dissented. In Judge Lourie’s view, the majority opinion and the Federal Circuit precedence on which it relies read the word “solely” out of the Safe Harbor. Judge Lourie believes that solely limits the application of the Safe Harbor to acts that have no purpose other than the development of information for the FDA. In other words, the Safe Harbor does not exist to protect acts that have a dual purpose, one of which is commercial. And here, factual disputes existed at least as to whether the accused infringer’s importation served a dual purpose—FDA approval and sales. Judge Lourie urged that consideration by the Federal Circuit en banc is warranted to consider the proper construction of the Safe Harbor provision.

Practice Tip: Parties who are actively developing products for which FDA approvals are required prior to commercial use should take care to ensure that any potential act of infringement preceding FDA approval is tied to the development of information that will be submitted to the FDA. Such activity is protected if it is reasonably related to an FDA submission; whereas activity that is solely commercial in nature is exempt from the Safe Harbor.  

Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd., No. 2022-1877, 2024 WL 1243032 (Fed. Cir. Mar. 25, 2024)

Share This Insight

Previous Entries

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.